Certus International

About Us

Edward M. Aten, MD

President & CEO


  B.S.                                                                      Business Administration/Accounting

                                                                              School of Business Administration

                                                                              University of Kansas

                                                                              Lawrence, Kansas


   Post Baccalaureate                                          Premedical Studies

                                                                              Stanford University

                                                                              Palo Alto, California


   M.D.                                                                    University of Health Sciences

                                                                              Chicago Medical School

                                                                              Chicago, Illinois



Edward M. Aten, MD has over 30 years of industry experience in clinical and regulatory affairs.  Dr. Aten has been President and Chief Executive Officer of Certus International, Inc., since March 1995.  In addition to his executive responsibilities, Dr. Aten provides clinical and regulatory consulting services to the pharmaceutical industry.


Prior to becoming President and CEO of Certus, Dr. Aten held the positions of Vice President of Medical Affairs at Diatide, Inc., where he directed the overall clinical development of technetium labeled peptides; and Vice President, Medical and Regulatory Affairs at Mallinckrodt Medical, Inc., where he directed Clinical Research and Regulatory Affairs worldwide.  At Mallinckrodt, Dr. Aten directed domestic and international Phase I - IV clinical research and domestic and international regulatory affairs.  He also participated actively in technology acquisition and due diligence performance and provided medical consultation to other corporate and divisional groups as needed.  Dr. Aten managed the development of product lines that included both therapeutic and diagnostic agents as well as medical devices, including iodinated contrast media, catheters and radiopharmaceuticals.


Prior to his ten years at Mallinckrodt, Dr. Aten was the Associate Director of Clinical Research for the Medical Department of Beecham Laboratories, where he was project leader and clinical monitor for Beecham’s beta-lactamase inhibitor formulations.  At Beecham Laboratories, Dr. Aten directed the preparation and submission of five investigational drug programs, including those for two currently-marketed products (Augmentin and Timentin).